Novel anticoagulants and laboratory testing

Research output: Contribution to journalReview article

34 Scopus citations

Abstract

The introduction of several oral direct anticoagulants within the past 2-3 years has dramatically changed clinical practice and has also impacted on utilization and interpretation of coagulation laboratory testing. This article reviews the effects of the oral thrombin inhibitor, dabigatran, and the oral factor Xa inhibitors, rivaroxaban and apixaban, on screening and diagnostic coagulation tests, and describes methods for measuring the their anticoagulant activity in plasma. Currently, there are evidence gaps regarding the role of laboratory testing for surveillance and management of adverse events associated with these new anticoagulants which do not require routine therapeutic drug monitoring. This is a rapidly changing field, and coagulation laboratory experts have a major role in ensuring patients receive appropriate testing and accurate interpretations of results.

Original languageEnglish
Pages (from-to)262-268
Number of pages7
JournalInternational Journal of Laboratory Hematology
Volume35
Issue number3
DOIs
StatePublished - Jun 1 2013

Keywords

  • Apixaban
  • Coagulation assays
  • Dabigatran
  • Direct oral anticoagulant
  • Rivaroxaban

Fingerprint Dive into the research topics of 'Novel anticoagulants and laboratory testing'. Together they form a unique fingerprint.

  • Cite this